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Aims: Liraglutide, a GLP-1 receptor agonist, regulates appetite via receptors in the brain.
Because of concerns regarding the potential of centrally-acting anti-obesity medications to
affect mental health, pooled neuropsychiatric safety data from all phase 2 and 3a randomized,
double-blind trials with liraglutide 3.0 mg were evaluated post hoc.
Methods: Data from the liraglutide weight-management programme were pooled. Across trials,
individuals with a body mass index ≥30 or ≥27 kg/m2 with weight-related comorbidities were
randomized to once-daily subcutaneous liraglutide 3.0 mg (n = 3384) or placebo (n = 1941),
both with a 500 kcal/d deficit diet, plus exercise. Adverse events related to neuropsychiatric
safety were collected in all trials. Additionally, in the phase 3a trials, validated mental-health
questionnaires were prospectively and systematically administered.
Results: In the pooled analysis of 5325 randomized and exposed individuals, rates of depres-
sion (2.1 vs 2.1 events/100 person-years) and anxiety (1.9 vs 1.7 events/100 person-years)
through adverse event reporting were similarly low in liraglutide and placebo groups. Nine
(0.3%) individuals receiving liraglutide and 2 (0.1%) receiving placebo reported adverse events
of suicidal ideation or behaviour. In phase 3a trials, mean baseline Patient Health
Questionnaire-9 scores of 2.8  3.0 vs 2.9  3.1 for liraglutide vs placebo improved to
1.8  2.7 vs 1.9  2.7, respectively, at treatment end; 34/3291 individuals (1.0%) receiving lir-
aglutide 3.0 mg vs 19/1843 (1.0%) receiving placebo reported suicidal ideation on the
Columbia-Suicide Severity Rating Scale.
Conclusions: Results of this exploratory pooled analysis provide no cause for concern regarding
the neuropsychiatric safety of treatment with liraglutide 3.0 mg in patients similar to those
included in the examined trials. Although there was a small numerical imbalance in suicidal
ideation with liraglutide through adverse event reporting, no between-treatment imbalances in
suicidal ideation/behaviour or depression were noted through prospective questionnaire
assessments.
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1 | INTRODUCTION
Obesity is a global health problem1 and is associated with multiple
comorbidities,2,3 premature mortality,4 impaired health-related qual-
ity of life5 and individual, societal and economic costs.6 While initi-
ally effective for many individuals, diet or behaviour modification
alone is often difficult to sustain and many individuals regain
weight upon discontinuation.2 Pharmacotherapy for chronic weight
management may serve as an adjunct to lifestyle intervention in
enabling individuals to achieve and sustain clinically relevant
weight loss.
Given that many of the approved anti-obesity medications are
centrally-acting appetite suppressants, neuropsychiatric safety has
become an area of interest.7–9 Rimonabant, the first selective cen-
tral cannabinoid (CB1) receptor antagonist, was never approved by
the Food and Drug Administration (FDA) because of concerns
regarding psychiatric adverse events, including depression, anxiety
and suicidal ideation.10 Rimonabant was withdrawn by the European
Medicines Agency (EMA) in 2009, leading to termination of devel-
opment of several CB1-receptor blockers for the treatment of obe-
sity.11,12 However, many potential treatments aimed at varied
molecular targets in the central nervous system (CNS) are still under
development.8,9,11 Adding to the complexity of the situation is the
fact that, in general, obese individuals have a higher prevalence of
neuropsychiatric disorders, such as depression, compared to the
general population.13,14
Liraglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist
that regulates appetite centrally via receptors in the hypothalamus
and other areas of the brain.15 Weight loss with liraglutide is
mediated by reduced appetite and energy intake rather than by
increased energy expenditure.16 The clinical development programme
for liraglutide concerning weight management comprised one phase
2 dose-finding trial, which demonstrated weight loss with liraglutide
doses up to 3.0 mg over 2 years,17 and a large global phase 3a pro-
gramme called SCALE (Satiety and Clinical Adiposity – Liraglutide
Evidence in individuals with and without diabetes). The SCALE pro-
gramme was designed to investigate the efficacy and safety of liraglu-
tide 3.0 mg in 4 randomized, double-blind, placebo-controlled trials
(1 during 3 years, 2 during 56 weeks and 1 during 32 weeks) in over
5300 adults. Treatment with liraglutide 3.0 mg led to observed mean
weight loss from baseline, ranging from 5.7% to 8.0% (6.0-8.4 kg)
depending on the SCALE trial, whereas mean weight loss in the pla-
cebo group ranged from 0.1% to 2.6% (0.1-2.8 kg).18–22 Liraglutide,
administered at a once-daily subcutaneous dose of 3.0 mg, is now
approved for weight management in several regions, including North
America and Europe.
This post hoc analysis evaluates pooled neuropsychiatric safety
data from the 5 randomized, double-blind and placebo-controlled
trials described above, including data from 2 mental health question-
naires that were used in the 4 SCALE trials. Because of the evolving
regulatory and safety concerns described above, psychiatric disor-
ders were identified as medical events of special interest in the
phase 3a liraglutide 3.0 mg clinical development programme, provid-
ing an opportunity for prospective evaluation of depression and
suicidality.
2 | METHODS
This is a post hoc analysis and comprehensive report of pooled neu-
ropsychiatric safety data from the liraglutide weight management
programme. The 5 trials were performed at clinical research sites in
accordance with the Declaration of Helsinki23 and Good Clinical Prac-
tice guidelines,24 and the respective protocols were approved by local
institutional review boards or ethics committees. All participants pro-
vided written informed consent before the trials began. See Table S1,
Supporting Information online, for further information about the
trials, including inclusion/exclusion criteria and primary endpoints; full
methodology details have been reported previously.17–22
2.1 | Participants
Each trial enrolled men and women with a body mass index (BMI) of
≥27 kg/m2 and with at least 1 weight-related comorbidity, or a BMI
of ≥30 kg/m2 (Table S1, Supporting Information). Key exclusion cri-
teria included type 1 or 2 diabetes (except for the SCALE Diabetes
trial which specifically enrolled individuals with type 2 diabetes), the
use of medications causing significant weight gain or loss, previous
bariatric surgery, or a history of chronic pancreatitis or idiopathic
acute pancreatitis. Psychiatric illness was not excluded in the phase
2 trial, as this was not a regulatory requirement at the time, but indi-
viduals were excluded from the phase 3a trials for the following rea-
sons: history of major depressive disorder within the last 2 years; a
Patient Health Questionnaire-9 (PHQ-9) score ≥ 15 (indicating mod-
erately severe/severe depression) at screening; history of other
severe psychiatric disorders; lifetime history of a suicide attempt; or
history of suicidal behaviour or suicidal ideation type 4 (active suicidal
ideation with some intent to act without specific plan) or type
5 (active suicidal ideation with specific plan and intent) according to
the Columbia-Suicide Severity Rating Scale (C-SSRS) during the
month before randomization.
2.2 | Interventions
All participants self-administered treatment with once-daily subcuta-
neous liraglutide or placebo in FlexPen devices (Novo Nordisk A/S,
Bagsværd, Denmark), starting at a dose of 0.6 mg with weekly 0.6-
mg increments to 3.0 mg. This pooled analysis compared data with
liraglutide 3.0 mg and placebo only; additional liraglutide doses were
investigated in the phase 2 dose-finding trial (1.2, 1.8 and 2.4 mg)
and the SCALE Diabetes trial (1.8 mg), but those doses were not
included in this analysis since they are not approved for weight man-
agement. Furthermore, for the phase 2 trial, only data up to 1 year
were included for liraglutide 3.0 mg and placebo; after that, all
liraglutide- or placebo-treated individuals were switched to treatment
with liraglutide 2.4 mg and, thereafter, to 3.0 mg.17 Diet and exercise
counselling, provided at approximately monthly intervals, was similar
across trials.17–22 Participants were advised (in groups or individually)
to follow a reduced-calorie diet with an energy deficit of ~500 kcal/d
below their estimated total energy expenditure, containing a maxi-
mum of 30% energy from fat, ~20% from protein and ~50% from car-
bohydrates. The diet was reinforced by the use of 3-day food diaries,
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and pedometers were provided to encourage participants to achieve
a recommended minimum of 150 min/wk of physical activity.
2.3 | Neuropsychiatric safety
In each trial, adverse events in the system organ classes of “psychia-
tric disorders” and “nervous system disorders” were identified using
MedDRA (Medical Dictionary for Regulatory Activities) coding. In the
phase 3a trials, psychiatric disorders were classified as medical events
of special interest to ensure that brief narratives were collected, also
for non-serious adverse events. These narratives were limited to a
free-text description of the event by the investigator, such as rele-
vant medical history.
In the phase 3a trials, 2 validated mental health questionnaires
were employed for detecting possible depression (PHQ-9)25 or suici-
dal ideation and behaviour (C-SSRS).26 These were completed at
screening, randomization and each visit to the clinic during treatment
(except the dose-titration visits in the SCALE Maintenance trial) and
each took approximately 10 minutes to complete. Suicidal behaviour
was defined as: (1) death by suicide, (2) suicidal attempts where there
was intention to die or (3) nonfatal, self-injurious acts committed
without intent to die.
The PHQ-9 was self-administered and consisted of 9 questions
used for detecting possible depression and monitoring treatment.25
The C-SSRS (available at http://www.cssrs.columbia.edu/) was admi-
nistered as an interview by the investigator or sufficiently trained
medical personnel.26 The investigator reviewed the PHQ-9 and C-
SSRS questionnaires for completeness, together with any reported
adverse events at each visit.
2.4 | Statistical analyses
All available randomized individuals who received at least 1 treatment
dose of liraglutide 3.0 mg or placebo from the 5 randomized, con-
trolled weight management trials were included in the analyses. For
the change from baseline to end-of-treatment in the PHQ-9 total
score, a treatment difference was estimated, using an ANCOVA
model that included the baseline PHQ-9 total score as a covariate
and treatment and trial as factors. None of the trials was powered to
identify differences in adverse event rates; hence, adverse events
were analysed using descriptive statistics and no testing for signifi-
cance was undertaken.
3 | RESULTS
3.1 | Participant characteristics
Baseline characteristics of the 5325 randomized and exposed indivi-
duals are displayed in Table 1, and were generally comparable for lira-
glutide 3.0 mg and placebo. At baseline, 9.1% of individuals in the
liraglutide 3.0 mg group and 10.6% of those in the placebo group had
a self-reported history of depression, and 7.2% vs 7.8% had a self-
reported history of anxiety. None had a history of suicide attempt or
self-injury.
TABLE 1 Demographics and baseline characteristics
Pooled trialsa
Liraglutide 3.0
mg
N = 3384
Placebo
N = 1941
Sex, n (%)
Female 2449 (72.4) 1374 (70.8)
Male 935 (27.6) 567 (29.2)
Age, years 46.6 (12.2) 46.6 (11.8)
Race, n (%)
White 2845 (84.1) 1651 (85.1)
Black/African-American 348 (10.3) 202 (10.4)
Asian 115 (3.4) 53 (2.7)
American Indian or Alaska Native 9 (0.3) 4 (0.2)
Native Hawaiian or other Pacific
Islander
5 (0.1) 4 (0.2)
Other 62 (1.8) 27 (1.4)
Ethnicity, n (%)
Hispanic 341 (10.1) 193 (9.9)
Body weight, kg 106.1 (21.4) 106.2 (22.2)
Body mass index, kg/m2 37.9 (6.4) 37.8 (6.5)
HbA1c, %b 5.6 (0.4) 5.6 (0.4)
Fasting plasma glucose, mmol/Lb 5.3 (0.6) 5.4 ( 0.6)
History of psychiatric disorder, n (%) 454 (13.4) 307 (15.8)
Depression (except suicide and self-
injury)
309 (9.1) 206 (10.6)
Suicide and self-injury 0 (0.0) 0 (0.0)
Anxiety 243 (7.2) 151 (7.8)
Receiving antidepressants, n (%) 306 (9.0) 197 (10.1)
Receiving anxiolytics, n (%) 91 (2.7) 53 (2.7)
Dyslipidaemia, n (%) 1166 (34.5) 618 (31.8)
Hypertension, n (%) 1296 (38.3) 755 (38.9)
Dyslipidaemia and hypertension, n (%) 716 (21.2) 376 (19.4)
History of cardiovascular disease, n (%) 311 (9.2) 172 (8.9)
SCALE Diabetes (individuals with
T2DM)
n = 423 n = 212
Duration of T2DM, years 7.5 (5.7) 6.7 (5.1)
HbA1c, % 7.9 (0.8) 7.9 (0.8)
Fasting plasma glucose, mmol/L 8.8 (1.9) 8.6 (1.8)
Abbreviations: HbA1C, glycated haemoglobin; SCALE, Satiety and Clinical
Adiposity – Liraglutide Evidence; SD, standard deviation; T2DM, type
2 diabetes mellitus.
Data are presented as mean (SD), unless otherwise stated, and are
reported for randomized individuals who were exposed to at least 1 dose
of liraglutide or placebo. Individuals from France were not required to
report race. Ethnicity was not collected in the phase 2 trial. Anxiety
includes the high-level terms “anxiety symptoms” and “anxiety disorders
not elsewhere classified.” Dyslipidaemia and hypertension were based on
reported medical history. Cardiovascular disease was based on standar-
dized (Medical Dictionary for Regulatory Activities; MedDRA) queries
regarding ischaemic heart disease, cardiac failure, central nervous system
haemorrhages, cerebrovascular conditions, and embolic and thrombotic
events.
aIncluding data from the 104-week phase 2 trial and the 4 phase 3a
SCALE trials (1 of 160 weeks’ duration, 2 of 56 weeks’ duration and 1 of
32 weeks’ duration). SCALE Obesity and Prediabetes had 2 parts: a 56-
week period for individuals with and without prediabetes. Individuals with
prediabetes at screening continued in the second part of the trial for up
to 160 weeks of treatment.
bIndividuals without T2DM.
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3.2 | Neuropsychiatric safety data by adverse event
reporting
3.2.1 | Adverse events
Adverse events in the system organ classes of psychiatric and ner-
vous system disorders in the pooled analysis across all 5 trials are
shown in Table 2. Overall rates of psychiatric disorder were similar
for liraglutide 3.0 mg and placebo. Most events were non-serious and
did not lead to participant withdrawal. Rates of depression, anxiety
and insomnia were similarly low in both treatment groups (Table 2),
though insomnia rates were marginally higher in the liraglutide group.
3.2.2 | Suicidal ideation and behaviour
Nine of 3384 individuals (0.3%, 0.2 events/100 person-years) in the
liraglutide 3.0 mg group vs 2 of 1941 (0.1%, <0.1 events/100 person-
years) in the placebo group reported adverse events of suicidal idea-
tion or behaviour. All except 3 individuals continued treatment and
all except 1 recovered from the events. The condition of the indivi-
dual who did not recover was considered chronic but stable at the
end of the study. Importantly, at the final trial visit, it was discovered
that this participant had a history of suicide attempt 12 years prior to
study enrolment, and thus, based on exclusion criteria, should not
have been enrolled. Weight loss for each individual at the time of the
event is shown in Table S2, Supporting Information. Of the
11 individuals reporting suicidal ideation or behaviour, all except 1 in
each treatment group (liraglutide, suicidal ideation event; placebo, sui-
cide attempt) reported having a past history of psychiatric disorders
(including major depression, depression, anxiety and insomnia) or life
stressors accompanying the events (Table S2, Supporting Information).
Ten of the 11 individuals were from the SCALE Obesity and Predia-
betes trial and 9 had prediabetes. Two of the 11 individuals reported
2 events each, giving 13 events in total. Of these 13 events, 7 occurred
after the first year of the SCALE Obesity and Prediabetes trial.
3.3 | Neuropsychiatric safety data through
prospective collection of mental health questionnaires
Two validated mental health questionnaires were employed in the
phase 3a trials, the PHQ-9 and the C-SSRS.
3.3.1 | Patient Health Questionnaire-9 (PHQ-9)
Mean  SD PHQ-9 scores at baseline were 2.8  3.0 (range, 0-14)
with liraglutide 3.0 mg vs 2.9  3.1 (range, 0-17) with placebo. Mean
PHQ-9 scores improved (decreased) to 1.8  2.7 vs 1.9  2.7, respec-
tively, at end-of-treatment (using last-observation-carried-forward
imputation), with an estimated treatment difference (95% confidence
interval) of −0.02 (−0.17 to 0.12). The mean maximum post-baseline
TABLE 2 Pooled psychiatric and nervous system disorders reported during treatment
Liraglutide 3.0 mg Placebo
N = 3384 N = 1941
Pooled trialsa N (%) E R N (%) E R
Psychiatric disorders
Overall events 412 (12.2) 557 11.0 206 (10.6) 273 10.8
Serious events 5 (0.1) 6 0.1 4 (0.2) 4 0.2
Events leading to withdrawal 11 (0.3) 14 0.3 14 (0.7) 15 0.6
Selected types of events
Depression 101 (3.0) 107 2.1 48 (2.5) 52 2.1
Serious events 1 (<0.1) 1 <0.1 1 (<0.1) 1 <0.1
Anxiety 92 (2.7) 96 1.9 41 (2.1) 44 1.7
Serious events 1 (<0.1) 1 <0.1 1 (<0.1) 1 <0.1
Insomnia 122 (3.6) 143 2.8 45 (2.3) 50 2.0
Serious events 0 (0.0) 0 0.0 0 (0.0) 0 0.0
Nervous system disorders
Overall events 1024 (30.3) 1869 36.9 507 (26.1) 874 34.6
Serious events 18 (0.5) 19 0.4 11 (0.6) 13 0.5
Events leading to withdrawal 30 (0.9) 36 0.7 9 (0.5) 9 0.4
Selected types of events
Headache 534 (15.8) 820 16.2 273 (14.1) 422 16.7
Serious events 0 (0.0) 0 0.0 1 (<0.1) 1 <0.1
Memory impairment 7 (0.2) 7 0.1 1 (<0.1) 1 <0.1
Serious events 0 (0.0) 0 0.0 0 (0.0) 0 0.0
Abbreviations: N, number of individuals; %, based on total N; E, number of events; R, event rate per 100 person-years; SCALE, Satiety and Clinical Adip-
osity – Liraglutide Evidence.
Data were for individuals in the safety analysis set (all exposed individuals) and show specific preferred terms from the Medical Dictionary for Regulatory
Activities (MedDRA) database.
aIncluding data from the phase 2 trial up to 52 weeks and 4 phase 3a SCALE trials (1 of 160 weeks’ duration, 2 of 56 weeks’ duration and 1 of 32 weeks’
duration). SCALE Obesity and Prediabetes had 2 parts: a 56-week period for individuals with and without prediabetes; individuals with prediabetes at
screening continued in the second part of the trial for up to 160 weeks of treatment.
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scores were 4.2  3.7 and 4.0  3.8 for liraglutide vs placebo, respec-
tively. Examining the highest PHQ-9 score observed at any time during
treatment for each participant, 8.3% vs 8.5% of individuals scored ≥10
(moderate depression or worse) and 1.9% vs 2.0% scored ≥15 (moder-
ately severe depression or worse) with liraglutide 3.0 mg vs placebo.
Treatment groups were similar in terms of proportion of participants
showing improvement or worsening from baseline to their maximum
total PHQ-9 score at any time of treatment (Table 3).
Mental health questionnaire information for individuals reporting
suicide-related adverse events is shown in Table S3, Supporting Infor-
mation. PHQ-9 total scores at baseline indicated no depression or mild
depression for all 11 individuals. Eight of the 11 individuals showed
increases during treatment in maximum PHQ-9 score from baseline,
with 2 scores in the moderately severe or severe depression category.
Question 9 of the PHQ-9 asks the respondent to report how often over
the previous 2 weeks he or she has “been bothered by thoughts that
you would be better off dead or of hurting yourself in some way?”
Of the 11 individuals reporting suicide-related events, the maximum
post-baseline response to this question was a 0 (“not at all”) for 5 in the
liraglutide group and both of those in the placebo group, a 1 (“several
days”) for 3 in the liraglutide group, and a 3 (“nearly every day”) for 1
liraglutide group member (see Supporting Information for details).
3.3.2 | Columbia-Suicide Severity Rating Scale (C-SSRS)
On the C-SSRS at baseline, 110 individuals (3.3%) in the liraglutide
3.0 mg group vs 67 (3.6%) in the placebo group reported suicidal
behaviour and/or ideation at some time during their life. Most
instances were of suicidal ideation, while 6 (0.2%) vs 2 (0.1%) indi-
viduals, respectively, reported suicidal behaviour. The above indivi-
duals were not excluded from the trials as the reported behaviour
did not occur in the month before randomization, as per exclusion
criteria. During treatment, 34 individuals (1.0%) receiving liraglutide
3.0 mg vs 19 individuals (1.0%) receiving placebo reported suicidal
ideation on the C-SSRS (Table 4). Most of these individuals (26/34,
76% in the liraglutide group and 19/19, 100% in the placebo
group) did not report accompanying suicidal ideation adverse
events.
For the 11 individuals reporting suicidal ideation or behaviour
adverse events, only 1 of 9 individuals in the liraglutide 3.0 mg group
reported suicidal ideation at baseline on the C-SSRS. Neither of the
2 individuals in the placebo group did so, and no individual in either
group reported suicidal behaviour on the C-SSRS at baseline. The indi-
vidual who reported suicidal ideation at baseline was not excluded as
the ideation did not occur in the month before randomization. The C-
SSRS captured suicidal ideation during treatment in 8 of the 11 indivi-
duals who reported such events (Table S3, Supporting Information).
The 3 individuals for whom events were not captured by C-SSRS
included 1 in the liraglutide group who reported depression with suici-
dal ideation, and 2 individuals in the placebo group who reported a
suicide attempt and a major depressive episode with contemplation
about suicide, respectively. The C-SSRS did not capture the suicidal
behaviour in either of the 2 individuals who reported a suicide
attempt.
TABLE 3 PHQ-9 results post-baseline for pooled phase 3a trialsa
Baseline PHQ-9 
category
End of treatment PHQ-9 category (n (%)) for Liraglutide 3.0 mg (N = 3291) / Placebo (N = 1843)
None Mild Moderate Moderately severe Severe
None
Liraglutide 3.0 mg
Placebo
1824 (55.4)
1039 (56.4)
564 (17.1)      
284 (15.4)
95 (2.9)
49 (2.7)
16 (0.5)
16 (0.9)
5 (0.2)
5 (0.3)
Mild
Liraglutide 3.0 mg
Placebo
207 (6.3)
120 (6.5)
313 (9.5)
177 (9.6)
89 (2.7)      
44 (2.4)
21 (0.6)      
6 (0.3)
6 (0.2)      
2 (0.1)
Moderate
Liraglutide 3.0 mg
Placebo
22 (0.7)
11 (0.6)
61 (1.9)
35 (1.9)
28 (0.9)
27 (1.5)
9 (0.3)
5 (0.3)
4 (0.1)
1 (0.1)
Moderately severeb
Liraglutide 3.0 mg
Placebo
0 (0.0)
2 (0.1)
0 (0.0)
1 (0.1)
0 (0.0)
0 (0.0)
0 (0.0)
1 (0.1)
0 (0.0)
0 (0.0)
Abbreviations: PHQ-9, Patient Health Questionnaire-9; SCALE, Satiety and Clinical Adiposity – Liraglutide Evidence.
Data were for individuals in the safety analysis set (all exposed individuals), and show the shift from randomization to maximum PHQ-9 total score during
treatment. Blue shading represents improvement and grey shading represents worsening. No shading denotes no change. No individuals were in the
severe category at randomization.
Total for no change was 2167 (65.8%) in the liraglutide group and 1247 (67.7%) in the placebo group. Total improved was 290 (8.8%) vs 169 (9.2%). Total
worsened was 809 (24.6%) vs 412 (22.4%). Total missing was 25 (0.8%) vs 15 (0.8%). The total score of the 9 items ranges from 0 to 27; total scores of
0 to 4 represent no depression, of 5 to 9 represent mild depression, of 10 to 14 represent moderate depression, of 15 to 19 represent moderately severe
depression and of 20 to 27 represent severe depression. A PHQ-9 score ≥ 15 at screening was exclusionary.
aIncluding data from the 4 phase 3a SCALE trials (1 of 160 weeks’ duration, 2 of 56 weeks’ duration and 1 of 32 weeks’ duration). SCALE Obesity and
Prediabetes had 2 parts: a 56-week period for individuals with and without prediabetes; individuals with prediabetes at screening continued in the second
part of the trial for up to 160 weeks of treatment.
bThree individuals changed to the moderately severe category (which was exclusionary at screening) between screening and baseline.
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3.4 | Neuropsychiatric safety data following
treatment discontinuation
All of the SCALE trials, except the SCALE Sleep Apnoea trial, had a
12-week off-treatment observational follow-up period to evaluate
withdrawal or rebound effects of discontinuing liraglutide treatment.
No neuropsychiatric safety signals, through adverse event reporting,
PHQ-9 or C-SSRS data collection at the end of the 12-week time
period, were evident to indicate any withdrawal or rebound effects.
4 | DISCUSSION
This was a pooled post hoc analysis of neuropsychiatric safety data
across weight management trials with liraglutide 3.0 mg. The overall
incidence of depression, anxiety and insomnia adverse events was
similarly low (≤3.6%) in both liraglutide 3.0 mg and placebo treatment
groups, with a small numerical imbalance not favouring liraglutide in
insomnia events and in suicidality ideation/behaviour. However, there
were no differences in depression or suicidality indicators when pro-
spectively assessed in the phase 3a programme, which excluded indi-
viduals with a history of severe psychiatric disorders or suicidal
ideation/behaviour, as reflected by detailed analysis of PHQ-9 scores
and categories and C-SSRS data. Furthermore, there was no indica-
tion of withdrawal or rebound adverse effects when liraglutide treat-
ment was discontinued.
Nine (0.3%) vs 2 (0.1%) individuals reported suicidal ideation or
behaviour adverse events; 8 of the 11 individuals continued treat-
ment and symptoms resolved in 10. The individual who did not
recover from suicidal ideation was randomized in error, as she had
a history of a suicide attempt 12 years previously; her condition
was considered chronic but stable at the end of the trial. Nine of
the 11 individuals had prediabetes, which, as with diabetes, has
been shown to be associated with symptoms of depression27; how-
ever, no one from the SCALE Diabetes trial reported suicidal idea-
tion/behaviour events. Nine of the 11 individuals had a history of
psychiatric disorders or life stressors accompanying the events.
Overall, no evidence suggests that a positive history of these types
of events should be a contraindication for treatment with
liraglutide.
Several studies have revealed positive associations between BMI
and some psychiatric disorders, including depression and anxiety,14
with some differences between men and women.13 In one epidemio-
logical study, individuals with obesity were 1.5 times more likely than
those of normal weight to report such disorders occurring during
their lifetime or in the past year, and anxiety rates were increased
not only in individuals with obesity, but also in those who were mod-
erately overweight.28 Individuals with obesity are also more likely to
experience insomnia, according to a recent review.29 There appears
to be a reciprocal link between depression and obesity,30 whereby
obesity can increase the risk of depression and, conversely, depres-
sion can predict the development of obesity.31 It is therefore impor-
tant that pharmacological treatment options for chronic weight
management that will not exacerbate depression and can be used
safely with antidepressants are available. As with this trial, no signal
for neuropsychiatric events was detected in trials of liraglutide at
doses up to 1.8 mg for management of hyperglycaemia in individuals
with type 2 diabetes, including the LEADER trial (Liraglutide Effect
and Action in Diabetes: Evaluation of Cardiovascular Outcome
Results),32,33 or in postmarketing surveillance. Nevertheless, and in
accordance with regulatory guidance, US prescribing information
states that patients treated with liraglutide 3.0 mg should be moni-
tored for depression or suicidal thoughts, and treatment should be
discontinued if symptoms develop; treatment should also be avoided
in patients with a history of suicidal attempts or active suicidal idea-
tion. However, no such text is included in the European summary of
product characteristics.
We note that the information obtained from adverse-event
reporting and that from questionnaires used in the SCALE trials were
not always concordant, even though the data were collected during
the same visits throughout the trials. For example, while a similar pro-
portion of individuals in the liraglutide 3.0 mg group (1.0%) and the
placebo group (1.0%) reported suicidal ideation on the C-SSRS, far
fewer individuals in both treatment groups reported adverse events
of suicidal ideation or behaviour. Furthermore, although 8 of the
11 individuals who reported suicidal ideation or behaviour adverse
events had increases in maximum total PHQ-9 scores during treat-
ment, these increased scores were in the moderately severe or severe
depression range in only 2 cases. The suicidal ideation events were
detected by the C-SSRS for 8 of the 11 individuals, all in the liraglu-
tide group, whereas neither adverse event of suicidal behaviour
(attempt) was detected by C-SSRS. Thus, longitudinal assessment of
neuropsychiatric safety in clinical trials may benefit from the combi-
nation of adverse event reporting and validated questionnaires, as
shown here.
TABLE 4 C-SSRS results post-baseline
Pooled phase 3a trialsa Liraglutide
3.0 mg
Placebo
N = 3291 N = 1843
Number of participants completing C-
SSRS
3270 1832
N (%) with suicidal ideation on the C-
SSRS
34 (1.03) 19 (1.03)
1. Wish to be dead 30 (0.91) 18 (0.98)
2. Active suicidal ideation, non-specific
thoughts
15 (0.46) 8 (0.43)
3. Active suicidal ideation, any method
(no plan) without intent
11 (0.33) 3 (0.16)
4. Active suicidal ideation, some intent
to act, without specific plan
2 (0.06) 1 (0.05)
5. Active suicidal ideation, specific plan
and intent
1 (0.03) 2 (0.11)
Abbreviations: C-SSRS, Columbia-Suicide Severity Rating Scale; N (%),
number and percentage of individuals; SCALE, Satiety and Clinical Adipos-
ity – Liraglutide Evidence.
Data were for individuals in the safety analysis set (all exposed individuals)
and represent responses obtained at any time during treatment. The num-
ber and percentage of specific ideation types sum to more than that of any
ideation because individuals may have more than 1 type over time.
aIncluding data from the 4 phase 3a SCALE trials (1 of 160 weeks’ dura-
tion, 2 of 56 weeks’ duration and 1 of 32 weeks’ duration). SCALE Obe-
sity and Prediabetes had 2 parts: a 56-week period for individuals with
and without prediabetes; individuals with prediabetes at screening contin-
ued in the second part of the trial for up to 160 weeks of treatment.
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A limitation of this analysis is that it was performed in a popula-
tion that was selected according to trial-specific eligibility criteria,
and does not necessarily cover the full spectrum of patients who
might be treated outside of clinical trials, as individuals at high-risk
for psychiatric disorders were excluded. Furthermore, the trial was
not powered to quantify a treatment effect on the event rate of psy-
chiatric disorders, suggesting the importance of further investigation.
While the PHQ-9 and the C-SSRS are validated mental-health ques-
tionnaires and may be useful as rapid assessment screening tools,
their limitations, as compared to longer structured assessments,
should also be noted. Strengths of the analysis include the overall
large sample size and the substantial exposure to liraglutide 3.0 mg in
the blinded trials, as well as the systematic prospective collection of
neuropsychiatric safety data by trained staff.
In conclusion, the results of this exploratory pooled analysis of
neuropsychiatric safety data from the liraglutide 3.0 mg weight man-
agement clinical development programme do not provide any clear
cause for concern regarding liraglutide 3.0 mg treatment in patients
who are similar to those included in the examined trials. Although
there was a small numerical imbalance in suicidal ideation with liraglu-
tide, as indicated through adverse event reporting, no between-
treatment imbalances in suicidal ideation/behaviour or depression
were noted through prospective questionnaire assessments. The
long-term safety and efficacy of anti-obesity medications are impor-
tant as individuals with obesity often require sustained therapy to
achieve and maintain weight loss. Neuropsychiatric safety should be
an integral component of any clinical risk/benefit assessment, and
the data provided here contribute to thoughtful and objective
decision-making and dialogue between patients and clinicians.
ACKNOWLEDGEMENTS
The contribution of all trial participants and trial site personnel who
helped conduct the trials is gratefully acknowledged. We would also
like to thank Michael Taulo Lund, MD, PhD and Hanna Hedman, PhD
(both Novo Nordisk employees) for contributing to the manuscript
reviews, as well as Angela Stocks, PhD (Larix A/S, Copenhagen, Den-
mark) for editorial and medical writing services, which were funded
by Novo Nordisk.
Conflict of interest
P. O. has received funding for research from Orexigen Therapeutics,
Weight Watchers International and Novo Nordisk, honoraria from
Novo Nordisk and Medscape/WebMD, and has been an advisory
board member for Orexigen Therapeutics, Janssen and Pfizer. V. A.
has received funding for research from AstraZeneca/BMS, Calibra,
Eisai, Elcelyx, Janssen, Novo Nordisk, Sanofi and Theracos and has
received consultancy fees from Adocia, ADA, AstraZeneca, Janssen,
Medscape, Novo Nordisk, Sanofi and Tufts, all within the last
12 months. A. A. has been an advisory board member for BioCare,
consultant for Basic Research, Gelesis, Novo Nordisk, Omega ACO,
Pathway Genomics, Pfizer, Sanofi-Aventis and S-Biotek and is a recipi-
ent of travel expenses and/or modest honoraria (<$2,000) for lectures
given at national and international meetings, often with support from
one or more corporate sponsors. He is co-inventor of a number of
patents owned by the University of Copenhagen, in accordance with
Danish law. He is a member of the board and a shareholder in the con-
sultancy company Dentacom Aps, Denmark, and is a co-founder and
co-owner of the University of Copenhagen spin-out company, Mobile
Fitness A/S, Denmark. He is also co-founder, co-owner and a member
of the board of the University of Copenhagen spin-out company Flax-
slim ApS, Denmark. R. K. serves on the advisory boards for Novo Nor-
disk, Weight Watchers, Retrofit and Zafgen, and has received grant
support, on behalf of Northwestern University, from Aspire Bariatrics,
Eisai and Novo Nordisk. D. L. has received research funding from
AstraZeneca, Boehringer-Ingelheim and Novo Nordisk, and has
received consultancy fees from Amgen, AstraZeneca, Boehringer-
Ingelheim, Novo Nordisk, Sanofi and Shire, and lecture fees from
Amgen, AstraZeneca, Boehringer-Ingelheim, Merck and Novo Nordisk.
T. W. serves on advisory boards for Novo Nordisk, Nutrisystem and
Weight Watchers and has received grant support, on behalf of the
University of Pennsylvania, from Eisai Co. and Novo Nordisk. J. B. and
A. C. are employed by and hold stock in Novo Nordisk. J. W. has
received grant funding (via his institution), consultancy and lecture
fees (institutional and personal) from Novo Nordisk, and consultancy
and lecture fees from AstraZeneca, Boehringer Ingelheim, Eli Lilly,
Janssen, Orexigen and Sanofi (both institutional and personal) in rela-
tion to treatments for obesity and/or diabetes.
Author contributions
Novo Nordisk provided overall management of the trials, performed
the statistical analyses and verified the accuracy of the presented
data. Novo Nordisk was also responsible for the overall trial designs,
and provided a formal review of the manuscript, but the authors had
final authority, including choice of journal. Under the direction of the
authors and according to an agreed outline, the medical writer,
Angela Stocks, drafted the initial version of the manuscript. A. A. par-
ticipated in the concept and design of the phase 2 trial. A. A. and
T. W. were signatory investigators on the phase 2 trial and the SCALE
Maintenance trial, respectively, and P. O., V. A., R. K., D. L. and J. W.
were also trial investigators. All authors were involved in the analysis
or interpretation of data, and all critically reviewed the manuscript
and approved the final version for submission. All authors also agreed
to be accountable for all aspects of the work.
ORCID
Patrick M. O'Neil http://orcid.org/0000-0002-0388-4046
REFERENCES
1. NCD Risk Factor Collaboration (NCD-RisC). Trends in adult body-
mass index in 200 countries from 1975 to 2014: a pooled analysis of
1698 population-based measurement studies with 19  2 million par-
ticipants. Lancet. 2016;387:1377-1396.
2. Ferguson C, David S, Divine L, et al. Obesity drug outcome measures.
A consensus report of considerations regarding pharmacologic inter-
vention. Department of Health Policy, School of Public Health and
Health Services, The George Washington University. August
14, 2012. http://sphhs.gwu.edu/releases/obesitydrugmeasures.pdf.
Acccessed October 12, 2016.
O'NEIL ET AL. 1535
3. Guh DP, Zhang W, Bansback N, Amarsi Z, Birmingham CL, Anis AH.
The incidence of co-morbidities related to obesity and overweight: a
systematic review and meta-analysis. BMC Public Health. 2009;9:88.
4. Flegal KM, Kit BK, Orpana H, Graubard BI. Association of all-cause
mortality with overweight and obesity using standard body mass
index categories: a systematic review and meta-analysis. JAMA.
2013;309:71-82.
5. Garner RE, Feeny DH, Thompson A, et al. Bodyweight, gender, and
quality of life: a population-based longitudinal study. Qual Life Res.
2012;21:813-825.
6. Lim SS, Vos T, Flaxman AD, et al. A comparative risk assessment of
burden of disease and injury attributable to 67 risk factors and risk fac-
tor clusters in 21 regions, 1990–2010: a systematic analysis for the
Global Burden of Disease Study 2010. Lancet. 2012;380:2224-2260.
7. Food and Drug Administration Center for Drug Evaluation and Research
(CDER). Guidance for industry. Suicidal ideation and behavior: prospec-
tive assessment of occurrence in clinical trials (draft guidance). 2012.
http://www.fda.gov/downloads/Drugs/Guidances/UCM225130.pdf.
Acccessed October 12, 2016.
8. Rodgers RJ, Tschop MH, Wilding JP. Anti-obesity drugs: past, present
and future. Dis Model Mech. 2012;5:621-626.
9. Kang JG, Park C. Anti-obesity drugs: a review about their effects and
safety. Diabetes Metab J. 2012;36:13-25.
10. Christensen R, Kristensen PK, Bartels EM, Bliddal H, Astrup A. Effi-
cacy and safety of the weight-loss drug rimonabant: a meta-analysis
of randomised trials. Lancet. 2007;370:1706-1713.
11. Sargent BJ, Moore NA. New central targets for the treatment of obe-
sity. Br J Clin Pharmacol. 2009;68:852-860.
12. Aronne LJ, Tonstad S, Moreno M, et al. A clinical trial assessing the
safety and efficacy of taranabant, a CB1R inverse agonist, in obese
and overweight patients: a high-dose study. Int J Obes (Lond).
2010;34:919-935.
13. Zhao G, Ford ES, Dhingra S, Li C, Strine TW, Mokdad AH. Depression
and anxiety among US adults: associations with body mass index. Int
J Obes (Lond). 2009;33:257-266.
14. Scott KM, Bruffaerts R, Simon GE, et al. Obesity and mental disorders
in the general population: results from the world mental health sur-
veys. Int J Obes (Lond). 2008;32:192-200.
15. Knudsen LB, Secher A, Hecksher-Sorensen J, Pyke C. Long-acting
glucagon-like peptide-1 receptor agonists have direct access to and
effects on pro-opiomelanocortin/cocaine- and amphetamine-
stimulated transcript neurons in the mouse hypothalamus. J Diabetes
Invest. 2016;7:56-63.
16. van Can J, Sloth B, Jensen CB, Flint A, Blaak EE, Saris WHM. Effects
of the once-daily GLP-1 analog liraglutide on gastric emptying, glyce-
mic parameters, appetite and energy metabolism in obese, non-
diabetic adults. Int J Obes (Lond). 2014;38:784-793.
17. Astrup A, Carraro R, Finer N, et al. Safety, tolerability and sustained
weight loss over 2 years with once-daily human GLP-1 analog, liraglu-
tide. Int J Obes (Lond). 2012;36:843-854.
18. Pi-Sunyer X, Astrup A, Fujioka K, et al. A randomized, controlled trial
of 3.0 mg of liraglutide in weight management. N Engl J Med.
2015;373:11-22.
19. le Roux C, Astrup A, Fujioka K et al. 3 years of liraglutide versus pla-
cebo for type 2 diabetes risk reduction and weight management in
individuals with prediabetes: a randomised, double-blind trial. Lancet
2017; 389:1399-1409.
20. Davies MJ, Bergenstal R, Bode B, et al. Efficacy of liraglutide for
weight loss among patients with type 2 diabetes: the SCALE Diabetes
randomized clinical trial. JAMA. 2015;314:687-699.
21. Wadden TA, Hollander P, Klein S, et al. Weight maintenance and
additional weight loss with liraglutide after low-calorie-diet-induced
weight loss: The SCALE Maintenance randomized study. Int J Obes
(Lond). 2013;37:1443-1451.
22. Blackman A, Foster G, Zammit G, et al. Effect of liraglutide 3.0 mg in
individuals with obesity and moderate or severe obstructive sleep
apnea: the SCALE Sleep Apnea randomized clinical trial. Int J Obes
(Lond). 2016;40:1310-1319.
23. World Medical Association Declaration of Helsinki: ethical principles for
medical research involving human subjects. JAMA. 2000;284:3043-
3045.
24. International Conference on Harmonisation. ICH harmonised tripar-
tite guideline: guideline for good clinical practice E6(R1). http://
www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/
Efficacy/E6/E6_R1_Guideline.pdf. Accessed January 12, 2017.
25. Kroenke K, Spitzer RL, Williams JB. The PHQ-9: validity of a brief
depression severity measure. J Gen Intern Med. 2001;16:606-613.
26. Posner K, Brown GK, Stanley B, et al. The Columbia-Suicide Severity
Rating Scale: initial validity and internal consistency findings from
three multisite studies with adolescents and adults. Am J Psychiatry.
2011;168:1266-1277.
27. Mezuk B, Lee H, Abdou CM, et al. Is ignorance bliss? Depression,
antidepressants, and the diagnosis of prediabetes and type 2 diabetes.
Health Psychol. 2013;32:254-263.
28. Petry NM, Barry D, Pietrzak RH, Wagner JA. Overweight and obesity
are associated with psychiatric disorders: results from the National
Epidemiologic Survey on Alcohol and Related Conditions. Psychosom
Med. 2008;70:288-297.
29. Hargens TA, Kaleth AS, Edwards ES, Butner KL. Association between
sleep disorders, obesity, and exercise: a review. Nat Sci Sleep.
2013;5:27-35.
30. Bornstein SR, Schuppenies A, Wong ML, Licinio J. Approaching the
shared biology of obesity and depression: the stress axis as the locus
of gene–environment interactions. Mol Psychiatry. 2006;11:892-902.
31. Luppino FS, de Wit LM, Bouvy PF, et al. Overweight, obesity, and
depression: a systematic review and meta-analysis of longitudinal stu-
dies. Arch Gen Psychiatry. 2010;67:220-229.
32. Marso SP, Daniels GH, Brown-Frandsen K, et al. Liraglutide and cardiovas-
cular outcomes in type 2 diabetes. N Engl J Med. 2016;375:311-322.
33. Blonde L, Russell-Jones D. The safety and efficacy of liraglutide with or
without oral antidiabetic drug therapy in type 2 diabetes: an overview of
the LEAD 1-5 studies. Diabetes Obes Metab. 2009;11(suppl 3):26-34.
SUPPORTING INFORMATION
Additional Supporting Information may be found online in the sup-
porting information tab for this article.
How to cite this article: O'Neil PM, Aroda VR, Astrup A,
et al. Neuropsychiatric safety with liraglutide 3.0 mg for
weight management: Results from randomized controlled
phase 2 and 3a trials. Diabetes Obes Metab. 2017;19:1529–
1536. https://doi.org/10.1111/dom.12963
1536 O'NEIL ET AL.
